Guo Zhong, Wang Jun, Dong Ying, Adams Andrew B, Shirasugi Nozomu, Kim Oliver, Hart John, Newton-West Marvin, Pearson Thomas C, Larsen Christian P, Newell Kenneth A
Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA.
Am J Transplant. 2003 Sep;3(9):1091-8. doi: 10.1034/j.1600-6143.2003.00127.x.
Tolerance-inducing strategies that infuse donor bone marrow cells in conjunction with costimulation blockade have not been applied to intestinal transplantation. Intestines from BALB/c mice were transplanted into C57BL/6 recipients treated with anti-CD40L mAb, CTLA4-Ig, donor bone marrow, and busulfan. The majority of mice transplanted after completion of this regimen developed hematopoietic macrochimerism, although the degree of chimerism varied widely between recipients, and experienced long-term allograft survival. T cells from these mice demonstrated donor-specific hyporesponsiveness in vitro. However, T cells from chimeric mice proliferated to donor alloantigen in vivo. Furthermore, chimeric mice bearing intestinal allografts were capable of rejecting subsequently placed donor-strain skin grafts. These data suggest that although long-term allograft survival occurs in the absence of acute or chronic rejection, recipient mice are not completely unresponsive to donor alloantigens. When intestinal transplantation was performed at the time of initial bone marrow infusion (initiation of the chimerism protocol), most recipients failed to develop chimerism and promptly rejected the intestinal allograft. Although this is the most effective protocol that we have tested using this stringent model of transplantation, our observations suggest that modifications will be necessary before it can be reliably applied to the transplantation of highly immunogeneic organs like the intestine.
将供体骨髓细胞与共刺激阻断相结合的诱导耐受策略尚未应用于肠道移植。将BALB/c小鼠的肠道移植到接受抗CD40L单克隆抗体、CTLA4-Ig、供体骨髓和白消安治疗的C57BL/6受体小鼠体内。在完成该方案后进行移植的大多数小鼠产生了造血大嵌合体,尽管不同受体之间的嵌合程度差异很大,并且经历了长期的同种异体移植存活。这些小鼠的T细胞在体外表现出供体特异性低反应性。然而,嵌合小鼠的T细胞在体内对供体同种异体抗原发生增殖反应。此外,携带肠道同种异体移植物的嵌合小鼠能够排斥随后植入的供体品系皮肤移植物。这些数据表明,尽管在没有急性或慢性排斥反应的情况下发生了长期同种异体移植存活,但受体小鼠对供体同种异体抗原并非完全无反应。当在初次输注骨髓时(启动嵌合方案时)进行肠道移植时,大多数受体未能形成嵌合体,并迅速排斥肠道同种异体移植物。尽管这是我们使用这种严格的移植模型测试过的最有效的方案,但我们的观察结果表明,在将其可靠地应用于像肠道这样的高免疫原性器官移植之前,还需要进行改进。